This site is intended for health professionals only
Tuesday 18 December 2018
Share |

Latest News

European Commission approval for self-administration of Xolair® across all indications

Monday 17th December 2018
Novartis has announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.
With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
Thu, 6 Dec 2018
Research shows 31% of medication administration errors in English and Welsh acute care trusts are due to omitted medicine or ingredient.
Mon, 3 Dec 2018
An opinion from the CHMP is expected in the second half of 2019
Fri, 30 Nov 2018
Cancer patients in England have a poorer survival rate than patients in other European countries, according to the Health Foundation.
Fri, 30 Nov 2018
Researchers exposed lung, ovarian and colon cancer cells, and mouse models, to conditions similar to those in the human body, and investigated how manipulating cell metabolism can make cancer more vulnerable to oncolytic viruses
Thu, 29 Nov 2018
A survey of people working within pharmaceutical industry within and outside the UK found growing negativity about the impact of Brexit on the UK healthcare sector
Thu, 29 Nov 2018
CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks.